Seelos Therapeutics (SEELQ) 10-K 9 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 24, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Entity File Number	000-22245
Entity Registrant Name	SEELOS THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	87-0449967
Entity Address, Address Line One	300 Park Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
City Area Code	(646)
Local Phone Number	293-2100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SEEL
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		108,110,790
Entity Public Float	$ 69.9
Entity Central Index Key	0001017491
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	Short Hills, NJ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 15,533	$ 78,734
Prepaid expenses and other current assets	7,141	4,727
Total current assets	22,674	83,461
Operating lease right-of-use asset	72	39
Total assets	22,746	83,500
Current liabilities
Accounts payable	3,626	1,693
Accrued expenses	7,282	3,728
Licenses payable	2,195	200
Short-term portion of convertible notes payable, at fair value	11,865	1,030
Derivative liability		1,174
Warrant liabilities, at fair value	132	424
Operating lease liability	58	38
Total current liabilities	25,158	8,287
Convertible notes payable, at fair value	8,184	17,890
Operating lease liability, long-term	15
Total liabilities	33,357	26,177
Commitments and contingencies (note 12)
Stockholders' equity (deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2022 and December 31, 2021
Common stock, $0.001 par value, 240,000,000 shares authorized, 107,168,256 and 105,500,445 issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	107	105
Additional paid-in-capital	204,026	198,428
Accumulated deficit	(214,744)	(141,210)
Total stockholders' equity (deficit)	(10,611)	57,323
Total liabilities and stockholders' equity (deficit)	$ 22,746	$ 83,500

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock ,authorized	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	240,000,000	240,000,000
Common stock, issued (in shares)	107,168,256	105,500,445
Common stock, outstanding (in shares)	107,168,256	105,500,445

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expense
Research and development	$ 58,620	$ 46,649
General and administrative	12,296	15,020
Total operating expense	70,916	61,669
Loss from operations	(70,916)	(61,669)
Other income (expense)
Interest income	121	113
Interest expense	(14)	(1,598)
Change in fair value of derivative liability		(369)
Change in fair value of convertible notes	(3,017)	230
Net loss on extinguishment of debt		(2,387)
Gain on forgiveness of debt		149
Change in fair value of warrant liabilities	292	(517)
Total other expense	(2,618)	(4,379)
Net loss and comprehensive loss	$ (73,534)	$ (66,048)
Net loss per share basic	$ (0.69)	$ (0.73)
Net loss per share diluted	$ (0.69)	$ (0.73)
Weighted-average common shares outstanding basic	106,342,171	90,890,061
Weighted-average common shares outstanding diluted	106,342,171	90,890,061

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.69)	$ (0.73)
Earnings Per Share, Diluted	$ (0.69)	$ (0.73)
Weighted Average Number of Shares Outstanding, Basic	106,342,171	90,890,061
Weighted Average Number of Shares Outstanding, Diluted	106,342,171	90,890,061

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, value at Dec. 31, 2020	$ 54	$ 77,680	$ (75,162)	$ 2,572
Common Stock, Shares, Outstanding, Beginning Balance (in shares) at Dec. 31, 2020	54,535,891
Stock-based compensation expense		8,347		8,347
Issuance Of Common Stock, Pursuant to 2021 Securities Purchase Agreements	$ 1	1,051		1,052
Extinguishment of beneficial conversion feature		(1,519)		(1,519)
Issuance of common stock, pursuant to 2021 Securities Purchase Agreements (in shares)	540,147
Issuance of common stock for conversion of debt		138		138
Issuance of common stock for conversion of debt, shares	69,065
Stock Issued During Period, Value, New Issues	$ 40	97,917		97,957
Issuance of common stock, net of issuance costs, shares	39,788,554
Issuance of common stock for license acquired	$ 3	4,830		4,833
Issuance of common stock for license acquired, shares	2,570,266
Issuance of common stock for settlement of debt		1,377		1,377
Issuance of common stock for settlement of debt (in shares)	406,250
Issuance of common stock, options exercised		102		102
Issuance of common stock, options exercised, shares	79,138
Issuance of common stock, ESPP		104		104
Issuance of common stock, ESPP, shares	80,009
Warrants exercised for cash	$ 7	8,401		8,408
Warrants exercised for cash, shares	7,431,125
Net loss			(66,048)	(66,048)
Ending balance, value at Dec. 31, 2021	$ 105	198,428	(141,210)	$ 57,323
Common Stock, Shares, Outstanding, Ending Balance (in shares) at Dec. 31, 2021	105,500,445			105,500,445
Stock-based compensation expense		5,073		$ 5,073
Agreement to repurchase common stock		(740)		$ (740)
Issuance of common stock in at-the-market offering, net of issuance costs (in shares)	350,000
Issuance of common stock, net of issuance costs, shares				350,000
Issuance of common stock in at-the-market offering, net of issuance costs	$ 1	151		$ 152
Issuance of common stock for license acquired	$ 1	840		841
Issuance of common stock for license acquired, shares	1,000,000
Issuance of common stock, options exercised		8		$ 8
Issuance of common stock, options exercised, shares	6,250			6,250
Issuance of common stock for prepaid services (in shares)	200,000
Issuance of common stock for prepaid services		167		$ 167
Issuance of common stock, ESPP		99		99
Issuance of common stock, ESPP, shares	111,561
Net loss			(73,534)	(73,534)
Ending balance, value at Dec. 31, 2022	$ 107	$ 204,026	$ (214,744)	$ (10,611)
Common Stock, Shares, Outstanding, Ending Balance (in shares) at Dec. 31, 2022	107,168,256			107,168,256

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (73,534)	$ (66,048)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	5,073	8,347
Research and development expense - license amendment	841	5,637
Research and development expense - Vyera repurchase	455
Change in fair value of warrant liability	(292)	517
Change in fair value of convertible notes payable	3,017	(230)
Change in fair value of derivative liability		369
Gain on forgiveness of debt		(149)
Amortization of right-of-use asset	53
Net loss on extinguishment of debt		2,387
Amortization of debt discount		1,582
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(2,247)	(2,894)
Accounts payable	1,933	(194)
Accrued expenses	3,522	1,806
Derivative liability	(1,174)
Lease liability	(51)
Licenses payable	800	(125)
Net cash used in operating activities	(61,604)	(48,995)
Cash flows (used in) provided by financing activities
Payment of convertible note	(1,888)	(13,551)
Proceeds from issuance of common stock, net of issuance costs		97,957
Proceeds from issuance of common stock and convertible notes payable		20,203
Proceeds from exercise of warrants		7,252
Proceeds from issuance of common stock in at-the-market offering	457
Payment of at-the-market offering issuance costs	(273)
Proceeds from exercise of options	8	102
Proceeds from sales of common stock under ESPP	99	104
Net cash (used in) provided by financing activities	(1,597)	112,067
Net (decrease) increase in cash	(63,201)	63,072
Cash, beginning of period	78,734	15,662
Cash, end of period	15,533	78,734
Supplemental disclosure of cash flow information:
Cash paid for interest	11	10
Non-cash investing and financing activities:
Reclass of warrant liabilities related to Series A warrants exercised for cash		1,155
Right-of-use assets obtained in exchange for operating lease liabilities	86	75
Issuance of common stock for convertible notes		69
Issuance of common stock for license payable	840
At-the-market offering issuance costs, accrued but not paid	32
Repurchase of common stock, accrued but not paid	$ 1,195
Issuance of common stock for settlement of debt		1,377
Issuance of common stock for iX Biopharma license		4,832
Extinguishment of beneficial conversion feature		$ 1,519

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Organization Seelos Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006 and SLS-007 for the potential treatment of Parkinson’s Disease (“PD”). Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) asset, operating lease liability, current and operating lease liability, long-term in the Company’s condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the transition date and commencement date in determining the present value of lease payments. This is the rate the Company would have to pay if it borrowed on a collateralized basis over a similar term to each lease. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Fair Value Option As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred. Fair Value Measurements The Company follows the accounting guidance in the FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The carrying amounts of financial instruments such as accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments. Research and Development Research and development costs are expensed as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. Income (Loss) Per Common Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding for the year ended December 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Dectember 31, ​ ​ 2022 ​ 2021 Outstanding stock options 10,400 7,306 Restricted stock units — 2,400 Outstanding warrants 2,545 2,635 Convertible debt 3,397 3,704 ​ 16,342 16,045 ​ Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company. Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed. Segment Information The Company operates under one segment which develops pharmaceutical products. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. ASU 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company has decided to early adopt the provisions of this ASU as of January 1, 2023 and the Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which amends disclosures to increase transparency of government assistance, including (i) the types of assistance, (ii) accounting for the assistance and (iii) the effect of the assistance on an entity’s financial statements. The standard is effective for all business entities for annual periods beginning after December 15, 2021; therefore, it is effective for the Company’s financial statements issued for the year ended December 31, 2022. While the adoption of this guidance did not have an impact on the Company’s consolidated balance sheet, statement of operations or disclosures for the year ended December 31, 2022, the adoption of this guidance may require additional disclosures in the Company’s financial statements in future periods if and when government assistance is received. In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company has limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2022, the Company had $15.5 million in cash and an accumulated deficit of $214.7 million. The Company has historically funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and the exercise of warrants (see Note 10). The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the date of filing of this Annual Report on Form 10-K. Based on such evaluation and the Company’s current plans (including the ongoing clinical programs for SLS-002, SLS-005 and other product candidates), which are subject to change, management believes that the Company’s existing cash and cash equivalents as of December 31, 2022 are not sufficient to satisfy its operating cash needs for at least one year and that there is substantial doubt of its ability to continue as a going concern within one year The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2022
Business Combination
Business Combination	3. Business Combination On January 24, 2019, the Company (which was formerly known as “Apricus Biosciences, Inc.”) (“Apricus”) completed the business combination with Seelos Therapeutics, Inc., a Delaware corporation (“STI”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization entered into on July 30, 2018 (the “Merger Agreement”). Pursuant to the Merger Agreement, (i) a former subsidiary of the Company merged with and into STI, with STI (renamed “Seelos Corporation”) continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger and (ii) the Company was renamed “Seelos Therapeutics, Inc.” (the “Merger”). The Merger was accounted for as a reverse recapitalization under U.S. GAAP because the primary assets of Apricus were nominal at the close of the Merger. STI was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons holding securities convertible, exercisable or exchangeable directly or indirectly for STI common stock owned the majority of the Company immediately following the effective time of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company, and (iii) STI’s management holds all key positions in the management of the combined company. STI acquired no tangible assets and assumed no employees or operation from Apricus. Additionally, Apricus’ intellectual property was considered to have no value. The remaining Apricus liabilities had a fair value of approximately $300 thousand. In connection with the Merger, the Company and STI entered into a Contingent Value Rights Agreement (the “CVR Agreement”). Pursuant to the CVR Agreement, Apricus stockholders received one contingent value right (“CVR”) for each share of Apricus common stock held of record immediately prior to the closing of the Merger. Each CVR represents the right to receive payments based on Apricus’ U.S. assets related to products in development, intended for the topical treatment of erectile dysfunction, which are known as Vitaros in certain countries outside of the United States (the “CVR Product Candidate”). In particular, CVR holders will be entitled to receive 90% of any cash payments (or the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the Merger, based on the sale or out-licensing of Apricus’ CVR Product Candidate intangible asset, including any milestone payments (the “Contingent Payments”), less reasonable transaction expenses. The Company is entitled to retain the first $500,000 and 10% of any Contingent Payments. The Company has agreed to pay up to $500,000 of such Contingent Payments that it receives to a third party pursuant to a settlement agreement between the Company and the third party. The Company assigned no value to the CVR Product Candidate intangible asset or the CVR in the acquisition accounting as of December 31, 2022.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
4. Fair Value Measurement	4. Fair Value Measurement The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were no other transfers between fair value measurement levels during the years ended December 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements ​ ​ as of December 31, 2022 ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Assets: ​ ​ ​ ​ Cash ​ $ 15,533 ​ $ — ​ $ — ​ $ 15,533 Liabilities: ​ ​ ​ ​ Convertible notes payable, at fair value ​ $ — ​ $ — ​ $ 20,049 ​ $ 20,049 Warrant liabilities, at fair value ​ — ​ — ​ 132 ​ 132 ​ ​ $ — ​ $ — ​ $ 20,181 ​ $ 20,181 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements ​ ​ as of December 31, 2021 ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Assets: ​ ​ ​ ​ Cash ​ $ 78,734 ​ $ — ​ $ — ​ $ 78,734 Liabilities: ​ ​ ​ ​ Convertible notes payable, at fair value ​ $ — ​ $ — ​ $ 18,920 ​ $ 18,920 Derivative liability, at fair value ​ 1,174 ​ — ​ — ​ 1,174 Warrant liabilities, at fair value ​ — ​ — ​ 424 ​ 424 ​ ​ $ 1,174 ​ $ — ​ $ 19,344 ​ $ 20,518 ​ The Company measures the 2021 Convertible Notes and warrant liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the 2021 Convertible Notes, derivative liability and warrant liabilities related to updated assumptions and estimates are recognized within the Consolidated Statements of Operations and Comprehensive Loss. The fair value of the 2021 Convertible Notes and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. Derivative Liability The derivative liability represented the fair value of the “Shortfall Amount” provision provided for in the license agreement with iX Biopharma Europe Limited. See Note 7. At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of $1.2 million in cash in January 2022. 2021 Convertible Notes The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Year Ended ​ ​ December 31, 2022 ​ December 31, 2021 Risk-free interest rate ​ 4.24 % ​ 0.90% - 0.95 % Volatility ​ 105 % ​ 113% - 114 % Dividend yield ​ — % ​ — % Contractual term (years) ​ 1.9 ​ 3.0 ​ Stock price ​ $ 0.68 ​ $ 1.74 - 1.95 ​ ​ Warrant Liabilities The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Year Ended ​ ​ December 31, 2022 ​ December 31, 2021 Risk-free interest rate ​ 4.71 % ​ 0.75 % Volatility ​ 91.90 % ​ 110.55 % Dividend yield ​ — % ​ — % Expected term (years) ​ 1.07 ​ 2.07 ​ Weighted-average fair value ​ $ 0.44 ​ $ 1.40 ​ ​ The following table is a reconciliation for the common stock warrant liabilities and 2021 Convertible Notes measured at fair value using Level 3 unobservable inputs (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ ​ ​ ​ ​ ​ notes, at fair ​ ​ Warrant liabilities ​ Derivative liability ​ value Balance as of December 31, 2020 ​ $ 1,062 ​ $ — ​ $ — Warrant liability reclassified to stockholders’ equity ​ ​ (1,155) ​ ​ — ​ ​ — Issuance of convertible notes, at fair value ​ — ​ — ​ 19,150 Issuance of derivative liability ​ — ​ 805 ​ — Change in fair value measurement of derivative liability ​ — ​ 369 ​ — Change in fair value measurement of convertible notes ​ — ​ — ​ (230) Change in fair value measurement of warrant liability ​ 517 ​ — ​ — Balance as of December 31, 2021 ​ $ 424 ​ $ 1,174 ​ $ 18,920 Settlement of derivative liability ​ — ​ (1,174) ​ — Principal payment of convertible notes, at fair value ​ — ​ — ​ (1,888) Change in fair value measurement of convertible notes ​ — ​ — ​ 3,017 Change in fair value measurement of warrant liability ​ (292) ​ — ​ — Balance as of December 31, 2022 ​ $ 132 ​ $ — ​ $ 20,049 ​ For the years ended December 31, 2022 and 2021, the changes in fair value of the 2021 Convertible Notes, derivative liability and warrant liability primarily resulted from the volatility of the Company’s common stock.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
5. Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Prepaid insurance ​ $ 104 ​ $ 59 Prepaid clinical costs ​ 6,837 ​ 4,481 Other ​ 200 ​ 187 Prepaid expenses and other current assets ​ $ 7,141 ​ $ 4,727 ​

Common Stock Offerings

Common Stock Offerings	12 Months Ended
	Dec. 31, 2022
Common Stock Offerings
Common Stock Offerings	6. Common Stock Offerings Open Market Sale Agreement On May 12, 2022, the Company entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through the Agent (the “Offering”). The Company also filed a prospectus supplement, dated May 12, 2022, with the Securities and Exchange Commission (the “SEC”) in connection with the Offering (the “Prospectus Supplement”) under the Company’s existing shelf Registration Statement on Form S-3, as amended (File No. 333-251356), which became effective on December 23, 2020 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares having an aggregate offering price of up to $50.0 million. Under the terms of the Sale Agreement, the Agent is entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Sale Agreement. The Company also reimburses the Agent for certain expenses incurred in connection with the Sale Agreement and agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2022, the Company sold an aggregate of 350,000 shares under the Sale Agreement, receiving net proceeds of $0.5 million. The Company currently intends to use any net proceeds from the Offering for general corporate purposes and to advance the development of its product candidates. Public Offerings On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $64.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $7.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. Stock Purchase Agreement with iX Biopharma Europe Limited On November 24, 2021, the Company entered in an exclusive license agreement and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”). As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $9.0 million, comprised of $3.5 million in cash and 2,570,266 restricted shares of the Company’s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the Company agreed to reimburse iXBEL for the difference in value (the “Shortfall Amount”) in the event the aggregate value of the 2,570,266 shares of the Company’s common stock at the time of registration and issuance was less than $5.5 million. The initial fair value of this Shortfall Amount was $0.8 million and in January 2022, the Company settled the Shortfall Amount by the payment of $1.2 million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability on the Consolidated Statement of Operations and Comprehensive Loss (see Note 4). Pre-Merger Financing On January 24, 2019, STI and Apricus closed a private placement transaction with certain accredited investors (the “Investors”), whereby, among other things, STI issued to investors shares of STI’s common stock immediately prior to the Merger in a private placement transaction (the “Financing”), pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors, as amended (the “Purchase Agreement”). Pursuant to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STI’s common stock, which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company’s common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of $4.15, subject to adjustment as provided therein (the “Series A Warrants”), most recently adjusted to a price per share of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per share of $0.001, subject to adjustment as provided therein (the “Series B Warrants” together with the Series A Warrants, the “Investor Warrants”), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 10). The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given the liability exceed the proceeds received, a loss of $5.0 million was recognized. On March 7, 2019, the Company entered into Amendment Agreements (collectively, the “Amendment Agreements”) with each Investor amending: (i) the Purchase Agreement, (ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March 7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements. At December 31, 2022, 0.3 million Series A Warrants remain unexercised.

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2022
License Agreements
License Agreements	7. License Agreements Acquisition of License from Ligand Pharmaceuticals Incorporated On September 21, 2016, the Company entered into a License Agreement (the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products. In connection with the closing of the Merger, the Company issued 801,253 shares of common stock to Ligand and recognized research and development expense totaling approximately $2.2 million during the three months ended March 31, 2019 for the License Agreement. The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the indication of Parkinson’s Disease (“PD”) or Restless Leg Syndrome, consisting of (i) $750,000 upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA approval of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product. The Company also agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product, (ii) $350,000 upon FDA approval of an application for such a particular Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $125,000 upon regulatory approval in a second Major Market for such a particular Licensed Product. The Company agreed to pay to Ligand certain one-time, non-refundable commercial milestone payments in connection with the Licensed Products, consisting of (i) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), (iv) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists, (v) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists. The Company will also pay to Ligand middle single-digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (“Vyera”) On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”). Pursuant to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount of $4.0 million on or before April 8, 2022 (the “Cash Payment”); (ii) issue to Vyera on or before April 11, 2022 500,000 shares of the Company’s common stock (the “Initial Shares”); (iii) issue to Vyera on or before July 11, 2022 an additional 500,000 shares of the Company’s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like) (the “July 2022 Shares”); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of the Company’s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company’s common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of the Company’s common stock (the “January 2023 Shares”, and together with the Cash Payment, the Initial Shares and the July 2022 Shares, the “Final Payments”). In consideration for the Final Payments, all of STI’s contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will terminate in full upon the date that all of the Final Payments have been made. On December 22, 2022, the Company entered into a Share Repurchase Agreement (the “Repurchase Agreement”) with Vyera, pursuant to which the Company agreed to repurchase the 500,000 Initial Shares and the 500,000 July 2022 Shares previously issued to Vyera for an aggregate purchase price of $1.2 million in January 2023. Refer to Note 14 “Subsequent Events” below for a subsequent event related to the Vyera Purchase Agreement. The Company paid the $4.0 million Cash Payment and issued the 500,000 Initial Shares to Vyera in April 2022. The Company issued the 500,000 July 2022 Shares to Vyera in July 2022, and subsequently agreed to repurchase the Initial Shares and the July 2022 Shares in January 2023 pursuant to the Repurchase Agreement on December 22, 2022. The Company recognized $5.8 million in research and development expense during the three months ended June 30, 2022 related to the Amendment, which consisted of the initial cash payment of $4.0 million and $0.8 million for the Initial Shares and the July 2022 Shares, which were measured at their grant-date fair value. The Company also recognized a liability of $1.0 million related to the January 2023 Shares within accrued licenses payable. The Company recognized a liability of $1.2 million related to the Repurchase Agreement, as well as $0.5 million in research and development expense for the premium paid for the repurchased shares. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of License from Stuart Weg, MD On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020, $0.125 million on January 2, 2021, and $0.2 million on January 3, 2022. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company’s common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the “Milestone Product”), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of Assets from Bioblast Pharma Ltd. (“Bioblast”) On February 15, 2019, the Company entered into an Asset Purchase Agreement (the “Bioblast Asset Purchase Agreement”) with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the “Bioblast Asset Purchase”). The Company paid to Bioblast $1.5 million in cash, and the Company paid to Bioblast an additional $2.0 million in February 2020. Accordingly, the Company recognized a $3.5 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, the Company agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in the future, as follows: (i) within 15 days following the completion of the Company’s first Phase II(b) clinical trial of Trehalose satisfying certain criteria, the Company will pay to Bioblast $8.5 million; and (ii) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates, the Company will pay to Bioblast $8.5 million. In addition, the Company agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative agreement with Team Sanfilippo Foundation (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome. On July 15, 2019, TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for a Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million towards the funding of the trial. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of License from The Regents of the University of California On March 7, 2019, the Company entered into an exclusive license agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (“UCLA”). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (“α-synuclein”). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (“CNS”). This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company’s license to a nonexclusive license. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of License from Duke University On June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes α-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022. Acquisition of License from iX Biopharma Europe Limited On November 24, 2021, the Company entered into an exclusive license agreement (the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of WafermineTM and certain other existing and to be developed iXBEL wafer-based delivery technologies, in all cases for sublingual administration of ketamine. In addition, iXBEL will supply the Company with sufficient product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted iXBEL an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake limited, non-exclusive research and development activities in the territory. The Company further agreed not to undertake certain activities with respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement. As consideration for the license under the iX License Agreement, the Company agreed to (i) pay iXBEL an upfront fee of $9.0 million, comprised of $3.5 million in cash and 2,570,266 restricted shares of its common stock; (ii) pay certain development, regulatory and commercial milestones, which, if achieved, aggregate to a total of $239.0 million; and (iii) pay royalty payments of ten percent on net sales, if any, as further set out in the iX License Agreement. Pursuant to the iXBEL Stock Purchase Agreement, the Company also agreed to reimburse iXBEL for the Shortfall Amount in the event the aggregate value of the 2,570,266 shares of its common stock issued to iXBEL pursuant to the iXBEL Stock Purchase Agreement was less than $5.5 million. The Shortfall Amount could be paid in cash, additional shares of common stock or a combination of both. As of December 31, 2021, the Company calculated the Shortfall Amount to be $1.2 million. The Company paid the Shortfall Amount of $1.2 million to iXBEL in cash in January 2022. The potential regulatory and commercial milestones are not yet considered probable, and no milestone payments have been accrued at December 31, 2022.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
8. Accrued Expenses	8. Accrued Expenses Accrued expenses are comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Professional fees ​ $ 278 ​ $ 181 Personnel related ​ 1,288 ​ 1,303 Outside research and development services ​ 5,627 ​ 2,219 Other ​ 89 ​ 25 Accrued expenses, net ​ $ 7,282 ​ $ 3,728 ​

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt
Debt	9. Debt Convertible Notes November 2021 and December 2021 Convertible Notes and Private Placement On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock. Commencing August 23, 2022, and from time to time and before the Maturity Date, Lind V has the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Commencing August 23, 2022, the Company has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2021 Notes, unless waived by Lind V in advance. Beginning on November 23, 2022, the 2021 Note amortizes in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties. On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note. On February 22, 2023, the December 2021 Notes were repaid in full. During the year ended December 31, 2021, the Company received aggregate gross proceeds of $20.2 million from the convertible note offerings. The Company elected to account for these notes under the fair value option. At time of issuance, the Company recorded a liability of $19.2 million, which was determined to be the fair value at time of issuance. As of December 31, 2022 and 2021, the Company recognized a total convertible note liability of $20.0 million and $18.9 million, respectively. During the year ended December 31, 2022 and 2021, the Company recognized $3.0 million loss and $0.2 million gain on change in fair value of convertible notes, respectively. During the year ended December 31, 2022, the Company made principal and interest payments of $1.9 million on the convertible notes. As of December 31, 2022, the principal and interest payment of the notes totaled $20.4 million. Scheduled maturities with respect to the 2021 Convertible Notes are as follows (in thousands): ​ ​ ​ ​ Year Ending December 31: ​ ​ 2023 ​ $ 11,111 2024 ​ $ 9,259 2025 ​ $ — 2026 ​ $ — 2027 ​ $ — Total ​ $ 20,370 ​ December 2020 Convertible Note and Private Placement On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the 2020 Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3 On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of our remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021. The Company received aggregate net proceeds of $10.9 million from the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million as of December 31, 2021. During the year ended December 31, 2021, the Company paid approximately $13.6 million in principal payments on the outstanding convertible notes and issued an aggregate of 475,315 shares of its common stock upon conversion of the convertible notes, and none of the 2020 convertible notes remain outstanding as of December 31, 2021. PPP Loan On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the “PPP Lender”), for an aggregate principal amount of approximately $147,000 (the “PPP Loan”). The PPP Loan bore interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, had a term of two years, and was unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program upon the Company’s request to the extent that the PPP Loan proceeds were used to pay expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company applied for and received full forgiveness of the PPP Loan with respect to these covered expenses and recorded a gain on forgiveness of debt during the year ended December 31, 2021.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
10. Stockholders' Equity	10. Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, par value $0.001. No shares of preferred stock were outstanding as of December 31, 2022 or 2021. Common Stock The Company has authorized 240,000,000 shares of common stock as of each of December 31, 2022 and 2021. Each share of common stock is entitled to one voting right. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of Directors. Warrants September 2020 Warrants On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued unregistered warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026. During the year ended December 31, 2022, no September 2020 Warrants were exercised. As of December 31, 2022, September 2020 Warrants exercisable for 1.0 million shares of common stock remain outstanding at an exercise price of $0.84 per share. August 2019 Warrants On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020 and will expire on August 28, 2023. During the year ended December 31, 2022, no August 2019 Warrants were exercised. As of December 31, 2022, August 2019 Warrants exercisable for 900,000 shares of common stock remain outstanding at an exercise price of $1.78 per share. Series A Warrants The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024. During the year ended December 31, 2022, no Series A Warrants were exercised. As of December 31, 2022, Series A Warrants exercisable for 0.3 million shares of common stock remain outstanding at an exercise price of $0.2957 per share. A summary of warrant activity during the year ended December 31, 2022 is as follows (warrants in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ Exercise ​ Contractual Life ​ Warrants Price (in years) Outstanding as of December 31, 2021 2,635 ​ $ 4.29 2.4 Issued — ​ $ — Exercised — ​ $ — Cancelled (90) ​ $ 47.06 Outstanding as of December 31, 2022 2,545 ​ $ 2.78 1.7 Exercisable as of December 31, 2022 2,545 ​ $ 2.78 1.7 ​ The Series A Warrants were recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation
11. Stock-based Compensation	11. Stock-Based Compensation The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1 st On May 15, 2020, the Company’s stockholders approved the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”), whereby qualified employees are allowed to purchase limited amounts of the Company’s common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1 st On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock, of which 646,465 shares of the Company’s common stock are available for future issuance as of December 31, 2022. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029. Stock options During the year ended December 31, 2022, the Company granted 660,605 incentive stock options and 2,299,395 non-qualified stock options to employees with a weighted average exercise price per share of $1.45 and a 10-year term, subject to the terms and conditions of the 2012 Plan or the 2019 Inducement Plan above. The stock options are subject to time vesting requirements. The stock options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years. During the year ended December 31, 2022, the Company also granted 140,000 non-qualified stock options to non-employee directors with a weighted average exercise price per share of $1.56 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the 12 months following the grant. The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. During the year ended December 31, 2022, 6,250 stock options were exercised and no options were forfeited. The following assumptions were used in determining the fair value of the stock options granted during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ December 31, 2022 December 31, 2021 Risk-free interest rate ​ 1.6%-3.4 % ​ 0.5%-1.2 % Volatility ​ 111%-113 % ​ 118%-125 % Dividend yield ​ — % ​ — % Expected term (years) ​ 5-6 ​ 5-6 ​ Weighted-average fair value $ 1.22 $ 3.46 ​ ​ A summary of stock option activity during the year ended December 31, 2022 is as follows (in thousands, except exercise prices and years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ Weighted- ​ Average ​ Total ​ ​ ​ ​ Average ​ Remaining ​ Aggregate ​ ​ Stock ​ Exercise ​ Contractual ​ Intrinsic ​ Options Price Life (in years) Value Outstanding as of December 31, 2021 7,306 ​ $ 2.60 ​ Granted 3,100 ​ 1.45 ​ Exercised (6) ​ 1.06 ​ Cancelled — ​ — ​ Outstanding as of December 31, 2022 10,400 ​ $ 2.26 8.0 ​ $ — Vested and expected to vest as of December 31, 2022 10,400 ​ $ 2.26 8.0 ​ $ — Exercisable as of December 31, 2022 4,545 ​ $ 2.70 7.5 ​ $ — ​ The intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $0.1 million and $0.3 million, respectively. As of December 31, 2022, unrecognized stock-option compensation expense of $7.5 million is expected to be realized over a weighted -average period of 2.2 years. Performance Stock Award During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the year ended December 31, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized. The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s consolidated statements of operations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Research and development ​ $ 932 ​ $ 717 General and administrative ​ 4,141 ​ 7,630 ​ ​ $ 5,073 ​ $ 8,347 12. ​

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	13. Income Taxes The Company has incurred net operating losses since inception. At December 31, 2022, the Company has available net operating loss carryforwards of approximately $104.2 million for federal income tax reporting purposes and approximately $90.8 million for state and local income tax reporting purposes. The net operating loss carryover of $104.2 million will be carried forward indefinitely. The state net operating loss carryover of $90.8 million will begin expiring in 2036. Deferred tax assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 2021 Net operating tax loss carryforwards ​ $ 27,362 ​ $ 30,751 Contingent payment obligations ​ 461 ​ 407 Stock based compensation ​ 1,559 ​ 3,208 R&E expenses ​ ​ 11,137 ​ ​ — Intangible assets ​ 8,577 ​ 16,970 Total deferred tax asset ​ 49,096 ​ 51,336 Less valuation allowance ​ (49,096) ​ (51,336) Net deferred tax asset ​ $ — ​ $ — ​ The federal and state net operating loss carryforwards, not subject to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of December 31, 2022 and 2021 of approximately $27.4 million and $30.8 million, respectively. In consideration of the Company’s accumulated losses and the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded a full valuation allowance as of such dates. Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company’s federal income tax returns for 2018 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. Unrecognized tax benefits, if recognized, would have no effect on the Company’s effective tax rate. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2022 and 2021, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. The Company did not have any unrecognized tax benefits for the years ended December 31, 2022 and 2021. The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2022 and 2021, are as follows: ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Federal statutory tax rate 21.0 % 21.0 % State and local taxes, net of federal benefit — % 12.9 % Permanent Items (1.0) % (1.1) % Deferred rate changes (12.9) % 2.3 % Deferred true-up (10.2) % — % Change in valuation allowance 3.1 % (35.1) % Income tax provision (benefit) — % — % 14. ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
12. Commitments and Contingencies	13. Commitments and Contingencies Leases In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder. In March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which ended in September 2022. In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month subject to periodic increases. Under the new office space rental agreement in October 2022, in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $86,000. As of December 31, 2022, the weighted-average remaining lease term of the operating lease was 1.3 years, and the weighted-average discount rate was 8.0%. As of December 31, 2022, future minimum lease payments for the Company’s operating lease with a non-cancelable term is as follows (in thousands): ​ ​ ​ ​ ​ Operating ​ ​ Leases Year Ended December 31, 2023 ​ $ 62 Year Ended December 31, 2024 ​ 16 Total ​ 78 Less present value discount ​ (5) Operating lease liabilities ​ $ 73 ​ For each of the years ended December 31, 2022 and 2021, operating lease expense totaled $0.1 million. Contractual Commitments The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash. Litigation As of December 31, 2022, there was no material litigation against the Company.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	14. Subsequent Events On January 3, 2023, the Company paid $1.2 million in cash to Vyera under the Repurchase Agreement to repurchase the 500,000 Initial Shares and the 500,000 July 2022 Shares. See Note 7 for further discussion of the Vyera Asset Purchase Agreement. On January 10, 2023, STI entered into Amendment No. 6 to the Vyera Purchase Agreement (“Amendment No. 6”) with Vyera, pursuant to which, STI agreed to make two cash payments to Vyera in an aggregate amount of $500,000 each on January 31, 2023 and February February On January 26, 2023, the Company and The General Hospital Corporation, doing business as Massachusetts General Hospital (“MGH”), entered into a Consortium Agreement, whereby the parties will collaborate on an Expanded Access Protocol for SLS-005 in patients with ALS under an award from the National Institutes of Health, which was awarded to MGH in September 2022. Under the Consortium Agreement, the Company is a subrecipient of the award, with the Company’s subaward totaling $2.9 million over a period ending August 31, 2025.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Seelos Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006 and SLS-007 for the potential treatment of Parkinson’s Disease (“PD”).
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) asset, operating lease liability, current and operating lease liability, long-term in the Company’s condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the transition date and commencement date in determining the present value of lease payments. This is the rate the Company would have to pay if it borrowed on a collateralized basis over a similar term to each lease. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Fair Value Option	Fair Value Option As permitted under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.
Fair Value Measurements	Fair Value Measurements The Company follows the accounting guidance in the FASB ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The carrying amounts of financial instruments such as accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments.
Research and Development	Research and Development Research and development costs are expensed as incurred and include milestone and upfront payments for license arrangements, the cost of employee compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
Income (Loss) Per Common Share	Income (Loss) Per Common Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding for the year ended December 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Dectember 31, ​ ​ 2022 ​ 2021 Outstanding stock options 10,400 7,306 Restricted stock units — 2,400 Outstanding warrants 2,545 2,635 Convertible debt 3,397 3,704 ​ 16,342 16,045 ​
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company. Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.
Segment Information	Segment Information The Company operates under one segment which develops pharmaceutical products.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. ASU 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company has decided to early adopt the provisions of this ASU as of January 1, 2023 and the Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which amends disclosures to increase transparency of government assistance, including (i) the types of assistance, (ii) accounting for the assistance and (iii) the effect of the assistance on an entity’s financial statements. The standard is effective for all business entities for annual periods beginning after December 15, 2021; therefore, it is effective for the Company’s financial statements issued for the year ended December 31, 2022. While the adoption of this guidance did not have an impact on the Company’s consolidated balance sheet, statement of operations or disclosures for the year ended December 31, 2022, the adoption of this guidance may require additional disclosures in the Company’s financial statements in future periods if and when government assistance is received. In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of antidilutive securities excluded from computation of diluted weighted average shares outstanding	The following potentially dilutive securities outstanding for the year ended December 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Dectember 31, ​ ​ 2022 ​ 2021 Outstanding stock options 10,400 7,306 Restricted stock units — 2,400 Outstanding warrants 2,545 2,635 Convertible debt 3,397 3,704 ​ 16,342 16,045 ​

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Schedule of Fair Value Hierarchy Assets and Liabilities	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were no other transfers between fair value measurement levels during the years ended December 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements ​ ​ as of December 31, 2022 ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Assets: ​ ​ ​ ​ Cash ​ $ 15,533 ​ $ — ​ $ — ​ $ 15,533 Liabilities: ​ ​ ​ ​ Convertible notes payable, at fair value ​ $ — ​ $ — ​ $ 20,049 ​ $ 20,049 Warrant liabilities, at fair value ​ — ​ — ​ 132 ​ 132 ​ ​ $ — ​ $ — ​ $ 20,181 ​ $ 20,181 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements ​ ​ as of December 31, 2021 ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Assets: ​ ​ ​ ​ Cash ​ $ 78,734 ​ $ — ​ $ — ​ $ 78,734 Liabilities: ​ ​ ​ ​ Convertible notes payable, at fair value ​ $ — ​ $ — ​ $ 18,920 ​ $ 18,920 Derivative liability, at fair value ​ 1,174 ​ — ​ — ​ 1,174 Warrant liabilities, at fair value ​ — ​ — ​ 424 ​ 424 ​ ​ $ 1,174 ​ $ — ​ $ 19,344 ​ $ 20,518 ​
Schedule of Fair Value Level 3 Reconciliation	The following table is a reconciliation for the common stock warrant liabilities and 2021 Convertible Notes measured at fair value using Level 3 unobservable inputs (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ ​ ​ ​ ​ ​ ​ ​ notes, at fair ​ ​ Warrant liabilities ​ Derivative liability ​ value Balance as of December 31, 2020 ​ $ 1,062 ​ $ — ​ $ — Warrant liability reclassified to stockholders’ equity ​ ​ (1,155) ​ ​ — ​ ​ — Issuance of convertible notes, at fair value ​ — ​ — ​ 19,150 Issuance of derivative liability ​ — ​ 805 ​ — Change in fair value measurement of derivative liability ​ — ​ 369 ​ — Change in fair value measurement of convertible notes ​ — ​ — ​ (230) Change in fair value measurement of warrant liability ​ 517 ​ — ​ — Balance as of December 31, 2021 ​ $ 424 ​ $ 1,174 ​ $ 18,920 Settlement of derivative liability ​ — ​ (1,174) ​ — Principal payment of convertible notes, at fair value ​ — ​ — ​ (1,888) Change in fair value measurement of convertible notes ​ — ​ — ​ 3,017 Change in fair value measurement of warrant liability ​ (292) ​ — ​ — Balance as of December 31, 2022 ​ $ 132 ​ $ — ​ $ 20,049 ​
Long-Term Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Fair Value Measurements Warrant Valuation Assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Year Ended ​ ​ December 31, 2022 ​ December 31, 2021 Risk-free interest rate ​ 4.24 % ​ 0.90% - 0.95 % Volatility ​ 105 % ​ 113% - 114 % Dividend yield ​ — % ​ — % Contractual term (years) ​ 1.9 ​ 3.0 ​ Stock price ​ $ 0.68 ​ $ 1.74 - 1.95 ​
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Summary of Fair Value Measurements Warrant Valuation Assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended Year Ended ​ ​ December 31, 2022 ​ December 31, 2021 Risk-free interest rate ​ 4.71 % ​ 0.75 % Volatility ​ 91.90 % ​ 110.55 % Dividend yield ​ — % ​ — % Expected term (years) ​ 1.07 ​ 2.07 ​ Weighted-average fair value ​ $ 0.44 ​ $ 1.40 ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Professional fees ​ $ 278 ​ $ 181 Personnel related ​ 1,288 ​ 1,303 Outside research and development services ​ 5,627 ​ 2,219 Other ​ 89 ​ 25 Accrued expenses, net ​ $ 7,282 ​ $ 3,728

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt
Schedule of maturities with respect to the 2021 Convertible Notes	Scheduled maturities with respect to the 2021 Convertible Notes are as follows (in thousands): ​ ​ ​ ​ Year Ending December 31: ​ ​ 2023 ​ $ 11,111 2024 ​ $ 9,259 2025 ​ $ — 2026 ​ $ — 2027 ​ $ — Total ​ $ 20,370 ​

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Warrant Activity	A summary of warrant activity during the year ended December 31, 2022 is as follows (warrants in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ Average ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ Exercise ​ Contractual Life ​ Warrants Price (in years) Outstanding as of December 31, 2021 2,635 ​ $ 4.29 2.4 Issued — ​ $ — Exercised — ​ $ — Cancelled (90) ​ $ 47.06 Outstanding as of December 31, 2022 2,545 ​ $ 2.78 1.7 Exercisable as of December 31, 2022 2,545 ​ $ 2.78 1.7 ​

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation
Schedule of Valuation Assumptions for Stock Options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ December 31, 2022 December 31, 2021 Risk-free interest rate ​ 1.6%-3.4 % ​ 0.5%-1.2 % Volatility ​ 111%-113 % ​ 118%-125 % Dividend yield ​ — % ​ — % Expected term (years) ​ 5-6 ​ 5-6 ​ Weighted-average fair value $ 1.22 $ 3.46 ​ ​
Summary of Stock Option Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ Weighted- ​ Average ​ Total ​ ​ ​ ​ Average ​ Remaining ​ Aggregate ​ ​ Stock ​ Exercise ​ Contractual ​ Intrinsic ​ Options Price Life (in years) Value Outstanding as of December 31, 2021 7,306 ​ $ 2.60 ​ Granted 3,100 ​ 1.45 ​ Exercised (6) ​ 1.06 ​ Cancelled — ​ — ​ Outstanding as of December 31, 2022 10,400 ​ $ 2.26 8.0 ​ $ — Vested and expected to vest as of December 31, 2022 10,400 ​ $ 2.26 8.0 ​ $ — Exercisable as of December 31, 2022 4,545 ​ $ 2.70 7.5 ​ $ — ​
Schedule of Stock-Based Compensation Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Research and development ​ $ 932 ​ $ 717 General and administrative ​ 4,141 ​ 7,630 ​ ​ $ 5,073 ​ $ 8,347

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of Deferred Tax Assets	Deferred tax assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2022 2021 Net operating tax loss carryforwards ​ $ 27,362 ​ $ 30,751 Contingent payment obligations ​ 461 ​ 407 Stock based compensation ​ 1,559 ​ 3,208 R&E expenses ​ ​ 11,137 ​ ​ — Intangible assets ​ 8,577 ​ 16,970 Total deferred tax asset ​ 49,096 ​ 51,336 Less valuation allowance ​ (49,096) ​ (51,336) Net deferred tax asset ​ $ — ​ $ — ​
Summary of reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes	The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2022 and 2021, are as follows: ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Federal statutory tax rate 21.0 % 21.0 % State and local taxes, net of federal benefit — % 12.9 % Permanent Items (1.0) % (1.1) % Deferred rate changes (12.9) % 2.3 % Deferred true-up (10.2) % — % Change in valuation allowance 3.1 % (35.1) % Income tax provision (benefit) — % — %

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization and Summary of Significant Accounting Policies
Antidilutive securities excluded	16,342	16,045
Outstanding stock options
Organization and Summary of Significant Accounting Policies
Antidilutive securities excluded	10,400	7,306
Restricted stock units
Organization and Summary of Significant Accounting Policies
Antidilutive securities excluded		2,400
Outstanding warrants
Organization and Summary of Significant Accounting Policies
Antidilutive securities excluded	2,545	2,635
Convertible debt
Organization and Summary of Significant Accounting Policies
Antidilutive securities excluded	3,397	3,704

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Segment Information (Details)	12 Months Ended
	Dec. 31, 2022 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segment	1

Liquidity and Going Concern (De

Liquidity and Going Concern (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 15,533	$ 78,734
Accumlated deficit	$ (214,744)	$ (141,210)
Substantial Doubt about Going Concern, within One Year [true false]	false

Business Combination (Details)

Business Combination (Details)	Jan. 24, 2019 USD ($) item employee
Business Combination
Total number of board seats of combined company | item	5
Contingent Value Rights Agreement
Business Combination
Number of CVR issued for each share of Apricus common stock held of record | item	1
Percentage of cash payments that CVR holders are entitled	90%
Threshold minimum amount for payment of cash at a certain percentage to CVR holders	$ 500,000
Period from Close of Merger for cash payments in excess of threshold specified amount	10 years
Amount that the Company is entitled to retain	$ 500,000
Percentage of Contingent Payments that the Company is entitled to retain	10%
Maximum amount of Contingent Payments that the Company has agreed to pay to a third party	$ 500,000
Seelos Therapeutics, Inc
Business Combination
Number of board seats of combined company held | item	4
Seelos Therapeutics, Inc | Merger Agreement
Business Combination
Tangible assets acquired	$ 0
Number of employees assumed | employee	0
Apricus Biosciences, Inc [Member]
Business Combination
Intangible asset	$ 0
Fair value of liabilities	$ 300,000

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)		1 Months Ended			12 Months Ended
	Nov. 24, 2021	Jan. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2022
Business Combination, Separately Recognized Transactions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net					$ 0
I X License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
[custom:NonrefundableCashPayment]	$ 3,500,000	$ 1,200,000	$ 1,200,000	$ 3,500,000

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Fair Value Hierarchy Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Warrant [Member]
Liabilities [Abstract]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]		Warrant Liabilities At Fair Value
Fair Value, Recurring [Member]
Assets
Cash	$ 15,533	$ 78,734
Liabilities [Abstract]
Total financial liabilities	20,181	20,518
Fair Value, Recurring [Member] | Long-Term Debt [Member]
Liabilities [Abstract]
Convertible notes payable, at fair value	20,049	18,920
Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Warrant liabilities, at fair value	132	424
Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities [Abstract]
Derivative liability, at fair value		1,174
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Assets
Cash	15,533	78,734
Liabilities [Abstract]
Total financial liabilities		1,174
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]
Liabilities [Abstract]
Derivative liability, at fair value		1,174
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Liabilities [Abstract]
Total financial liabilities	20,181	19,344
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]
Liabilities [Abstract]
Convertible notes payable, at fair value	20,049	18,920
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Liabilities [Abstract]
Warrant liabilities, at fair value	$ 132	$ 424

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Long-Term Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.24%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	105%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	1 year 10 months 24 days	3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.68
Long-Term Debt [Member] | Minimum [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.90%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		113%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price		$ 1.74
Long-Term Debt [Member] | Maximum [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.95%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		114%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price		$ 1.95
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	6 years	6 years

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.71%	0.75%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	91.90%	110.55%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	1 year 25 days	2 years 25 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.44	$ 1.40

Fair Value Measurement - Sche_2

Fair Value Measurement - Schedule of Fair Value Level 3 Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	$ 424	$ 1,062
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3		(1,155)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	(292)	517
Balance at ending	132	424
Long-Term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	18,920
Settlement of derivative liability		(19,150)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	3,017	(230)
Principal payment of convertible notes, at fair value	(1,888)
Balance at ending	20,049	18,920
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at beginning	1,174
Settlement of derivative liability	$ (1,174)	(805)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings		369
Balance at ending		$ 1,174

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 104	$ 59
Prepaid clinical costs	6,837	4,481
Other	200	187
Prepaid expenses and other current assets	$ 7,141	$ 4,727

Common Stock Offerings (Details

Common Stock Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands								1 Months Ended			12 Months Ended
	Dec. 22, 2022	Jul. 22, 2022	May 12, 2022	Nov. 24, 2021	May 24, 2021	Jan. 28, 2021	Jan. 24, 2019	Jan. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 07, 2019	Jan. 25, 2019
Subsidiary, Sale of Stock [Line Items]
Aggregate future offering amount			$ 50,000
Commission rate on gross proceeds of common stock sale			3%
Number of shares of common stock issued	500,000	500,000			22,258,066	17,530,488					350,000
Sale of Stock, Price Per Share					$ 3.10	$ 2.05
[custom:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes]					$ 7,300	$ 3,800
Research and Development Expense											$ 58,620	$ 46,649
Number of shares that the holder has right to receive upon merger					2,903,226	2,286,585
Number of shares called by warrants issued														1,463,519
Exercise price of warrants														$ 4.15
Loss recognized											(292)	$ 517
Receiving net proceeds											$ 500
Investor Warrants
Subsidiary, Sale of Stock [Line Items]
Fair value of warrants							$ 21,500
Loss recognized							$ 5,000
Series A Warrants
Subsidiary, Sale of Stock [Line Items]
Number of shares called by warrants issued											3,629,023
Exercise price of warrants									$ 0.2957		$ 0.2957	$ 0.2957
Pre-Merger Financing | Seelos Therapeutics, Inc
Subsidiary, Sale of Stock [Line Items]
Number of shares of common stock issued							2,374,672
Sale of stock consideration received on transaction							$ 16,500
Number of shares that the holder has right to receive upon merger							1,829,407
Adjusted exercise price of warrants							$ 0.2957
Gross proceeds							$ 18,000
Pre-Merger Financing | Seelos Therapeutics, Inc | Series A Warrants
Subsidiary, Sale of Stock [Line Items]
Number of shares called by warrants issued							1,463,519						3,629,023
Exercise price of warrants							$ 4.15
Number of warrants exercised													0
Number of warrants remain unexercised											300,000
Pre-Merger Financing | Seelos Therapeutics, Inc | Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Number of shares called by warrants issued							0
Exercise price of warrants							$ 0.001
I X License Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Research and Development Expense				$ 9,000						$ 9,000
[custom:NonrefundableCashPayment]				$ 3,500				$ 1,200	$ 1,200	$ 3,500
[custom:Issuanceofcommonstockforlicenseacquiredshares]				2,570,266						2,570,266
[custom:MinimumStockValueOfSharesIssued]				$ 5,500						$ 5,500
[custom:InitialStockValuationShortfallFrom5.5MillionValue]				$ 800					$ 1,200

License Agreements (Details)

License Agreements (Details) - USD ($)														1 Months Ended						3 Months Ended		12 Months Ended
	Jan. 11, 2023	Dec. 22, 2022	Jul. 22, 2022	Apr. 11, 2022	Jan. 03, 2022	Jan. 02, 2022	Nov. 24, 2021	May 24, 2021	Jan. 28, 2021	Jan. 02, 2021	Jan. 02, 2020	Feb. 15, 2019	Sep. 21, 2016	Jul. 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Feb. 29, 2020	Jun. 30, 2022	Mar. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Business Combination, Separately Recognized Transactions [Line Items]
Stock Issued During Period, Shares, New Issues		500,000	500,000					22,258,066	17,530,488													350,000
Research and development expense - Vyera repurchase																						$ 500,000
Research and development																						58,620,000	$ 46,649,000
Non refundable Cash Payment																						1,200,000
Issuance of common stock, net of issuance costs	$ 1,000,000							$ 64,500,000	$ 33,500,000														97,957,000
Other Accrued Liabilities, Current																	$ 25,000					89,000	$ 25,000
Total aggregate																						$ 239,000,000
Assetsfrom Vyera Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description																						On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”
Stock Issued During Period, Shares, New Issues				500,000										500,000	500,000
Research and development																				$ 5,800,000
Aggregate purchase price			$ 1,200,000
Cash payment															$ 4,000,000							$ 4,000,000
License agreement description																						On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”
Issuance of common stock, net of issuance costs														$ 800,000
Other Accrued Liabilities, Current																						$ 1,000,000
Cash Payments Agreedtoin Amendment to the Asset Purchase Agreement																						4,000,000
Licensefrom Ligand Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description													On September 21, 2016, the Company entered into a License Agreement (the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.
Stock Issued During Period, Shares, New Issues																					801,253
Research and development expense - Vyera repurchase																					$ 2,200,000
Contingent non-refundable regulatory milestone payment upon submission of an application																						750,000
Contingent non-refundable regulatory milestone payment upon FDA approval of an application for a particular Licensed Product																						1,125,000
Contingent non-refundable regulatory milestone payment upon FDA approval of an application for a particular Licensed Product																						350,000
contingent non-refundable regulatory milestone payment in connection with aplindore upon regulatory approval In major market for such particular licensed product																						100,000
Contingent Nonrefundable Regulatory Milestone Payment In Connection With Aplindore Upon Fda Approval Of Application For Such Particular Licensed Product																						3,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 1.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Aplindore																						10,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 1.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon H3 Receptor Antagonist																						10,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 1.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Acetaminophen																						10,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 1.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Crth2Antagonists																						10,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement of 2.0 billion of cumulative world wide net sales of licensed products based upon aplindore																						20,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 2.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Acetaminophen																						20,000,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 2.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Crth2 Antagonists																						20,000,000
Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist																						20,000,000
Contingent nonrefundable regulatory milestone payment in connection with aplindore.																						125,000
Milestone payments accrued																						0
License agreement description													On September 21, 2016, the Company entered into a License Agreement (the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products. The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0
Weg License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description																						On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020, $0.125 million on January 2, 2021, and $0.2 million on January 3, 2022. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company’s common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the “Milestone Product”), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.
Non refundable Cash Payment						$ 200,000				$ 125,000	$ 100,000
Milestone payments accrued																						$ 0
Contingent nonrefundable milestone share value of common stock payment upon issuance of first patent directed to anxiety indication					$ 150,000
License agreement description																						On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020, $0.125 million on January 2, 2021, and $0.2 million on January 3, 2022. As further consideration, the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by the closing sales price of the Company’s common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval from the EMA in the EU, for such product (the “Milestone Product”), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon regulatory approval by the EMA for the Milestone Product, (v) $1.5 million upon regulatory approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v) will be $6.6 million. The Company will also pay to Dr. Weg a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.
Non-refundable cash payment					200,000
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0
Contingent nonrefundable milestone payment upon fda approval of nda for milestone product.																						3,000,000
Contingent nonrefundable milestone payment					$ 100,000
Contingent nonrefundable milestone payment after locking of database																						500,000
Contingent nonrefundable milestone payment upon regulatory approval by ema for milestone product																						2,000,000
Contingent nonrefundable milestone payment upon regulatory approval in japan for milestone product																						1,500,000
Maximum amount to be paid under milestones																						$ 6,600,000
Percentage of royalty payments																						2.25%
Assets from Bioblast Pharma [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Research and development																								$ 3,500,000
Milestone payments accrued																						$ 0
Non-refundable cash payment												$ 1,500,000							$ 2,000,000
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0
Percentage of royalty payments												1%
Contingent additional milestone consideration												$ 8,500,000
Future grant revenue contingent												$ 1,500,000
U C Regents License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description																						On March 7, 2019, the Company entered into an exclusive license agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (“UCLA”). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (“α-synuclein”). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (“CNS”). This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company’s license to a nonexclusive license.
Research and development																								100,000
Contingent Milestone Payment Within Ninety Days Following Completion Of Dosing Of First Patient In Phase I Clinical Trial																						$ 50,000
Contingent Milestone Payment Within Ninety Days Following Dosing Of First Patient In Phase Ii Clinical Trial																						100,000
Contingent Milestone Payment Within Ninety Days Following First Commercial Sales In Any European Market																						1,000,000
Contingent milestone payment within 90 Days following 250 million in cumulative world wide net sales of licensed product																						2,500,000
Contingent Nonrefundable Commercial Milestone Payments In Connection With Achievement Of 1.0 Billion Of Cumulative Worldwide Net Sales Of Licensed Products Based Upon Aplindore																						125,000
Milestone payments accrued																						$ 0
License agreement description																						On March 7, 2019, the Company entered into an exclusive license agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created by researchers at the University of California, Los Angeles (“UCLA”). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (“α-synuclein”). The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (“CNS”). This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $0.1 million and recognized a $0.1 million charge to research and development expense during the year ended December 31, 2019. Under the terms of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following the dosing of the first patient in a Phase I clinical trial, the Company will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $0.3 million; (iv) within 90 days following the first commercial sales in the U.S., the Company will pay $1.0 million; (v) within 90 days following the first commercial sales in any European market, the Company will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide net sales of a licensed product, the Company will pay $2.5 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement or reduce the Company’s license to a nonexclusive license.
Non-refundable cash payment																								100,000
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0
Duke License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description																						On June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes α-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement.
Research and development																								100,000
Contingent Milestone Payment Within Thirty Days Following Filing Of Ind Following Completion Of Preclinical Studies Including Comprehensive Validation Of Platform																						$ 100,000
Contingent Milestone Payment Within Thirty Days Following Dosing Of First Patient In Phase Clinical Trial																						200,000
Contingent Milestone Payment Within Thirty Days Following Nda Approval																						2,000,000
Contingent milestone payment within 30days following dosing Of first patient phase Iii clinical trial.																						1,000,000
Contingent milestone payment within 30 days following dosing Of first patient In phase Ii clinical trial																						500,000
Milestone payments accrued																						$ 0
License agreement description																						On June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the SNCA gene, which encodes α-synuclein expression. The Company plans to study this initial approach in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon entry into the Duke License Agreement, the Company paid to Duke University $0.1 million and recognized $0.1 million charge to research and development expense during the year ended December 31, 2019. The Company agreed to pay additional consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company will pay $0.1 million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay $0.2 million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $1.0 million; and (v) within 30 days following an NDA approval, the Company will pay $2.0 million. The Company is also obligated to pay a single digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, Duke University may terminate the agreement.
Non-refundable cash payment																								$ 100,000
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0
I X License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description																		On November 24, 2021, the Company entered into an exclusive license agreement (the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of WafermineTM and certain other existing and to be developed iXBEL wafer-based delivery technologies, in all cases for sublingual administration of ketamine. In addition, iXBEL will supply the Company with sufficient product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted iXBEL an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake limited, non-exclusive research and development activities in the territory. The Company further agreed not to undertake certain activities with respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement.
Research and development							$ 9,000,000											$ 9,000,000
Milestone payments accrued																						0
License agreement description																		On November 24, 2021, the Company entered into an exclusive license agreement (the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and commercialization of WafermineTM and certain other existing and to be developed iXBEL wafer-based delivery technologies, in all cases for sublingual administration of ketamine. In addition, iXBEL will supply the Company with sufficient product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted iXBEL an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake limited, non-exclusive research and development activities in the territory. The Company further agreed not to undertake certain activities with respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement.
Non-refundable cash payment							3,500,000									$ 1,200,000	1,200,000	$ 3,500,000
Shortfall amount							$ 800,000										$ 1,200,000
Issuance of common stock for license acquired, shares							2,570,266											2,570,266
Asset Acquisition, Contingent Consideration, Liability, Current																						$ 0

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Professional fees	$ 278	$ 181
Personnel related	1,288	1,303
Outside research and development services	5,627	2,219
Other	89	25
Accrued expenses, net	$ 7,282	$ 3,728

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	1 Months Ended				12 Months Ended		24 Months Ended	27 Months Ended
	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2020	May 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Nov. 24, 2024	Nov. 23, 2024	Dec. 02, 2021
Debt
Loss on extinguishment of debt						$ (2,387)
Outstanding convertible notes					$ 20,370
Gain (loss) on change in fair value of convertible notes					(3,017)	230
Principal and interest payments of notes					1,888	13,551
November 2021 Lind securities purchase agreement
Debt
Long-Term Debt, Description		On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock.
August 23, 2022, Maturity date
Debt
Long-Term Debt, Description								Commencing August 23, 2022, and from time to time and before the Maturity Date, Lind V has the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Commencing August 23, 2022, the Company has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.
Amortization of November 2021 Lind securities purchase agreement
Debt
Long-Term Debt, Description							Beginning on November 23, 2022, the 2021 Note amortizes in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties.
December 2021 separate securities purchase agreements
Debt
Long-Term Debt, Description	On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note. On February 22, 2023, the December 2021 Notes were repaid in full.
Gross proceeds from convertible debt	$ 20,200
Convertible subordinated debt	18,900				20,000	18,900			$ 19,200
Outstanding convertible notes					20,400
Gain (loss) on change in fair value of convertible notes					3,000	200
Principal and interest payments of notes					$ 1,900
Lind securities purchase agreement
Debt
Long-Term Debt, Description			On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the 2020 Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (662/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of our remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.
December 2017 separate securities purchase agreements
Debt
Long-Term Debt, Description			On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of our remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.
Gross proceeds from convertible debt						10,900
Net issuance costs	500					500
Loss on extinguishment of debt						1,000
Reduction in additional paid-in capital						1,500
Repayments of convertible debt						$ 13,600
Aggregate shares of common stock upon conversion of convertible notes						475,315
Outstanding convertible notes	$ 0					$ 0
Paycheck protection program
Debt
Long-Term Debt, Description				On May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the “PPP Lender”), for an aggregate principal amount of approximately $147,000 (the “PPP Loan”). The PPP Loan bore interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, had a term of two years, and was unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program upon the Company’s request to the extent that the PPP Loan proceeds were used to pay expenses permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company applied for and received full forgiveness of the PPP Loan with respect to these covered expenses and recorded a gain on forgiveness of debt during the year ended December 31, 2021
Aggregate principal amount				$ 147,000

Debt - Maturities with respect

Debt - Maturities with respect to the 2021 Convertible Notes (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Scheduled maturities with respect to Convertible Notes
2023	$ 11,111
2024	9,259
Total	$ 20,370

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands							12 Months Ended
	Dec. 22, 2022	Jul. 22, 2022	May 24, 2021	Jan. 28, 2021	Sep. 04, 2020	Aug. 23, 2019	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2019	Jan. 25, 2019
Class of Warrant or Right [Line Items]
Preferred stock, authorized (in shares)							10,000,000	10,000,000
Preferred stock, per value (in usd per share)							$ 0.001	$ 0.001
Preferred stock, outstanding (in shares)							0	0
Common stock, authorized (in shares)							240,000,000	240,000,000
Common stock voting right							Each share of common stock is entitled to one voting right
Number of shares of common stock issued	500,000	500,000	22,258,066	17,530,488			350,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 4.15
Proceeds from exercise of warrants								$ 7,252
Number of shares called by warrants issued										1,463,519
September 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Date on which warrants became exercisable							Mar. 09, 2021
Warrants exercisable as of June 30, 2021							1,000,000
August 232019 [Member]
Class of Warrant or Right [Line Items]
Number of shares of common stock issued						4,475,000
September 2020 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares of common stock issued					8,865,000		6,648,750
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.84
Number of warrants exercised							0
August 2019 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares of common stock issued						2,237,500
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.78		$ 1.78
Proceeds from exercise of warrants							$ 0
Warrants exercisable as of June 30, 2021							900,000		2,237,500
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.2957	$ 0.2957
Proceeds from exercise of warrants							$ 0
Warrants exercisable as of June 30, 2021							300,000
Number of shares called by warrants issued							3,629,023
Series A Warrants [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.60
Series A Warrants [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.2957

Summary of Warrant Activity (De

Summary of Warrant Activity (Details) - Warrant Derivative Financial Instruments [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Offsetting Assets [Line Items]
Outstanding as of December 31, 2021	2,635
Outstanding as of December 31, 2021 , weighted-average exercise price (in usd per share)	$ 4.29
Warrants outstanding as of December 31, 2021 , weighted-average remaing contractual life (in years)		2 years 4 months 24 days
Cancelled	(90)
Cancelled, exercise price of warrants	$ 47.06
Outstanding as of December 31, 2022	2,545	2,635
Outstanding as of December 31, 2021, weighted-average exercise price (in usd per share)	$ 2.78	$ 4.29
Warrants outstanding as of December 31, 2021, weighted-average remaing contractual life (in years)	1 year 8 months 12 days
Warrants exercisable as of December 31, 2022	2,545
Exercisable, weighted-average exercise price (in usd per share)	$ 2.78
Warrants exercisable as of December 31, 2021, weighted-average remaing contractual life (in years)	1 year 8 months 12 days

Schedule of Valuation Assumptio

Schedule of Valuation Assumptions for Stock Options (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.22	$ 3.46
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.016%	0.005%
Volatility, minimum	1.11%	1.18%
Expected term (in years)	5 years	5 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, maximum	0.034%	0.012%
Volatility, maximum	1.13%	1.25%
Expected term (in years)	6 years	6 years

Summary of Stock Option Activit

Summary of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercised	(6,250)
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding as of December 31, 2020	7,306,000
Outstanding, beginning of period (USD per share) | $ / shares	$ 2.60
Granted	3,100,000
Granted in period (USD per share) | $ / shares	$ 1.45
Exercised	(6,000)
Exercised in period (USD per share) | $ / shares	$ 1.06
Outstanding as of March 31, 2022	10,400,000
Outstanding, end of period (USD per share) | $ / shares	$ 2.26
Outstanding - weighted-average remaining contractual life (in years)	8 years
Vested and expected to vest, end of period (shares)	10,400,000
Vested and expected to vest stock, end of period (USD per share) | $ / shares	$ 2.26
Weighted-average remaining contractual life (in years) of vested and expected to vest stock options	8 years
Exercisable, end of period (shares)	4,545,000
Exercisable, end of period (USD per share) | $ / shares	$ 2.70
Weighted-average remaining contractual life (in years) of exercisable stock options	7 years 6 months

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Noncash Expense	$ 5,073	$ 8,347
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Noncash Expense	932	717
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Noncash Expense	$ 4,141	$ 7,630

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jan. 01, 2022	May 15, 2020	Jan. 01, 2020	Dec. 31, 2022	Dec. 31, 2021
Stock-based Compensation
Stock-based compensation expense				$ 5,073	$ 8,347
Stock option exercised				6,250
Stock options forfeited				0
Employee stock option
Stock-based Compensation
Description of share-based compensation arrangement by share-based payment award				The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan.
Number of additional shares authorized	4,713,637
Number of shares authorized				15,817,818
Number of shares available for future grants				5.4
Purchase price of common stock (in percent)		85%
Options granted in period				3,100,000
Weighted-average exercise price per share granted in period				$ 1.45
Stock option exercised				6,000
Intrinsic value of options exercised				$ 100	300
Unrecognized stock option compensation expense				$ 7,500
Weighted average period for recognition				2 years 2 months 12 days
Employee stock purchase plan
Stock-based Compensation
Description of share-based compensation arrangement by share-based payment award				On May 15, 2020, the Company’s stockholders approved the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”), whereby qualified employees are allowed to purchase limited amounts of the Company’s common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company’s common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company’s Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the year ended December 31, 2022, the Company sold 111,561 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $51,000 for the year ended December 31, 2022.
Number of additional shares authorized			1,055,004
Number of shares authorized		1,000,000
Purchase price of common stock				111,561
Purchase price discount of common stock (in percent)				15%
Stock-based compensation expense				$ 51,000
2019 Inducement Plan
Stock-based Compensation
Description of share-based compensation arrangement by share-based payment award				On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock, of which 646,465 shares of the Company’s common stock are available for future issuance as of December 31, 2022. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.
Number of shares authorized				1,000,000
Common stock are available for future issuance				646,465
Incentive stock option
Stock-based Compensation
Options granted in period				660,605
Weighted-average exercise price per share granted in period				$ 1.45
Term of option grant				10 years
Vesting percentage on the first anniversary				25%
Non qualified stock options to employees
Stock-based Compensation
Options granted in period				2,299,395
Non qualified stock options to non employee directors
Stock-based Compensation
Options granted in period				140,000
Weighted-average exercise price per share granted in period				$ 1.56
Term of option grant				10 years
Vesting period				12 months
Performance stock award | Performance stock unit award to Executive
Stock-based Compensation
Stock-based compensation expense				$ 1,300	$ 4,900
Terms of award				During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the year ended December 31, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized.
Fair value of common stock					2,400,000
weighted average fair value					$ 4.31
Compensation cost				$ 0

Income Taxes - net operating lo

Income Taxes - net operating loss carryforwards (Details) - USD ($)	24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Noncurrent deferred tax asset, gross	$ 27,400,000	$ 30,800,000
Tax examination penalties and interest expense	0
Federal income tax reporting purposes
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	104,200,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	104,200,000
State and local income tax reporting purposes
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 90,800,000

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Net operating tax loss carryforwards	$ 27,362	$ 30,751
Contingent payment obligations	461	407
Stock-based compensation	1,559	3,208
R&E expenses	11,137
Intangible assets	8,577	16,970
Total deferred tax asset	49,096	51,336
Less valuation allowance	$ (49,096)	$ (51,336)

Income Taxes - Deferred tax a_2

Income Taxes - Deferred tax assets, narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Noncurrent deferred tax asset, federal and state net operating loss carryforwards	$ 27,362	$ 30,751

Income Taxes - Deferred tax a_3

Income Taxes - Deferred tax assets, narrative (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes
Federal statutory tax rate	21%	21%
State and local taxes, net of federal benefit		12.90%
Permanent items	(1.00%)	(1.10%)
Deferred rate changes	(12.90%)	2.30%
Change in valuation allowance	3.10%	(35.10%)
Other	(10.20%)

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset	$ 72	$ 39
Operating Lease, Liability, Current	58	38
Operating Lease, Liability	73
Operating Lease, Expense	100	$ 100
Lease base rent per month	$ 3,800
March 2019 Lease [Member]
Lessee, Lease, Description [Line Items]
Lease term	9 months
March 2021 Lease [Member]
Lessee, Lease, Description [Line Items]
Lease term	18 months
October 2022 Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset	$ 86,000
Operating Lease, Weighted Average Remaining Lease Term	1 year 3 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	8%
Lease base rent per month	$ 4,000
Lease term	18 months
November 2019 Lease [Member]
Lessee, Lease, Description [Line Items]
Lease base rent per month	$ 9,000
Additional lease term	12 months
November 2020 Lease [Member]
Lessee, Lease, Description [Line Items]
Additional lease term	12 months

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Future minimum lease payments for the Company's operating lease with a non-cancelable term
Year Ended December 31, 2023	$ 62
Year Ended December 31, 2024	16
Total	78
Less present value discount	(5)
Operating lease liabilities	$ 73

Subsequent Events - Purchase an

Subsequent Events - Purchase and repurchase agreement (Details) - Subsequent events	Feb. 28, 2023 USD ($)	Jan. 31, 2023 USD ($)	Jan. 26, 2023 USD ($)	Jan. 10, 2023 item	Jan. 03, 2023 USD ($) shares
Vyera Purchase Agreement
Subsequent Event [Line Items]
Number of cash payments | item				2
Payments for purchase of assets	$ 500,000	$ 500,000
Vyera Purchase Agreement | January 2023 Shares [Member]
Subsequent Event [Line Items]
Payments for purchase of assets	$ 500,000	$ 500,000
Repurchase Agreement
Subsequent Event [Line Items]
Payments to repurchase shares					$ 1,200,000
Repurchase Agreement | Initial Shares
Subsequent Event [Line Items]
Number of shares repurchased | shares					500,000
Repurchase Agreement | July 2022 Shares
Subsequent Event [Line Items]
Number of shares repurchased | shares					500,000
Consortium Agreement
Subsequent Event [Line Items]
Subaward under the agreement			$ 2,900,000